Angiotensin II converting enzyme inhibition improves survival, ventricular remodeling and myocardial energetics in experimental aortic regurgitation.
|Authors:||Arsenault, Marie; Zendaoui, Adnane; Roussel, Élise; Drolet, Marie-Claude; Dhahri, Wahiba; Grenier, Audrey; Gascon, Suzanne; Sarrhini, Otman; Rousseau, Jacques A.; Lecomte, Roger; Couët, Jacques|
|Abstract:||Background— Aortic valve regurgitation (AR) is a volume-overload disease causing severe eccentric left ventricular (LV) hypertrophy and eventually heart failure. There is currently no approved drug to treat patients with AR. Many vasodilators including angiotensin-converting enzyme inhibitors have been evaluated in clinical trials, but although some results were promising, others were inconclusive. Overall, no drug has yet been able to improve clinical outcome in AR and the controversy remains. We have previously shown in an animal model that captopril (Cpt) reduced LV hypertrophy and protected LV systolic function, but we had not evaluated the clinical outcome. This protocol was designed to evaluate the effects of a long-term Cpt treatment on survival in the same animal model of severe aortic valve regurgitation. Methods and Results—Forty Wistar rats with AR were treated or untreated with Cpt (1 g/L in drinking water) for a period of 7 months to evaluate survival, myocardial remodeling, and function by echocardiography as well as myocardial metabolism by µ positron emission tomography scan. Survival was significantly improved in Cpt-treated animals with a survival benefit visible as soon as after 4 months of treatment. Cpt reduced LV dilatation and LV hypertrophy. It also significantly improved the myocardial metabolic profile by restoring the level of fatty acids metabolic enzymes and use. Conclusions—In a controlled animal model of pure severe aortic valve regurgitation, Cpt treatment reduced LV remodeling and LV hypertrophy and improved myocardial metabolic profile and survival. These results support the need to reevaluate the role of angiotensin-converting enzyme inhibitors in humans with AR in a large, carefully designed prospective clinical trial.|
|Document Type:||Article de recherche|
|Issue Date:||17 September 2013|
|Open Access Date:||15 November 2017|
|This document was published in:||Circulation. Heart failure, Vol. 6 (5), 1021–1028 (2013)|
Lippincott Williams & Wilkins
|Collection:||Articles publiés dans des revues avec comité de lecture|
Files in this item:
|Arsenault et al version révisée 18 juin.pdf||359.51 kB||Adobe PDF|
All documents in CorpusUL are protected by Copyright Act of Canada.